1
|
Wang L, Zhang R, Liu J, Xu R, Zhao L, Li E, Zhang Y. An online survey on public awareness of drug clinical trials in inland cities of northern China. Front Public Health 2024; 12:1276536. [PMID: 38665243 PMCID: PMC11043599 DOI: 10.3389/fpubh.2024.1276536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Accepted: 03/25/2024] [Indexed: 04/28/2024] Open
Abstract
Objective The aims of this survey were to investigate the public awareness of drug clinical trials (DCTs) and willingness to participate the DCTs, and provide references for propaganda and science popularization of DCTs. Methods A self-designed questionnaire named "an online survey questionnaire on public awareness of DCTs" was used to conduct an online survey from January to March 2022. The demographic characteristics and the response of participants to the awareness and willingness to participate the DCTs were collected. The factors affecting the public awareness of DCTs were analyzed by single factor and binary logistic regression analysis. Results One thousand three hundred eighty valid questionnaires were collected, and the respondents' awareness rate of DCTs was 61.1%. Thirteen demographic characteristics including age, gender, education, occupation, work fields, household type, marital status, city type, income, medical insurance, medical expenditure, pressure to seek medical care, financial pressure, both significantly affected the qualified rate of participants' awareness of DCTs (p < 0.001) by single factor analysis. Binary logistic regression analysis indicated that education level, work fields, city type, medical insurance, and medical expenditure affected independently the participants' awareness rate of DCTs (p < 0.001). 52.9% of the participants were willing to take part in DCTs. "to promote medical progress" (54.4%) or "believe doctors" (31.1%) were the most frequent reasons for subjects participating in DCTs. Conclusion The public awareness rate of DCTs and the willingness to participate in drug clinical were significantly affected by the demographic characteristics of subjects. Thus, targeting the needs of the public, propaganda, and science popularization of DCTs should be carried out and served public health.
Collapse
Affiliation(s)
- Li Wang
- Department of Scientific Research, Faculty of General Family Medicine, the First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, China
- Department of Health Statistics, Faculty of Public Health, Shaanxi University of Chinese Medicine, Xi’an, Shannxi, China
| | - Ruiguang Zhang
- Xi’an Evidence Based Pharmaceutical Technology Co., Ltd, Xi’an, China
| | - Jingxuan Liu
- Department of Health Statistics, Faculty of Public Health, Shaanxi University of Chinese Medicine, Xi’an, Shannxi, China
| | - Rui Xu
- Department of Scientific Research, Faculty of General Family Medicine, the First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, China
| | - Lili Zhao
- Department of Scientific Research, Faculty of General Family Medicine, the First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, China
| | - Enze Li
- Department of Scientific Research, Faculty of General Family Medicine, the First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, China
| | - Yurong Zhang
- Department of Scientific Research, Faculty of General Family Medicine, the First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, China
| |
Collapse
|
2
|
Yadav S, Todd A, Patel K, Tabriz AA, Nguyen O, Turner K, Hong YR. Public knowledge and information sources for clinical trials among adults in the USA: evidence from a Health Information National Trends Survey in 2020. Clin Med (Lond) 2022; 22:416-422. [PMID: 38589062 PMCID: PMC9595001 DOI: 10.7861/clinmed.2022-0107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Lack of clinical trial awareness has been identified as a barrier to clinical trial recruitment. Identifying factors associated with clinical trial knowledge could inform ongoing efforts to improve diversity in clinical trials. METHODS Using data from the Health Information National Trends Survey, 2020, we examined the knowledge of clinical trials, associated characteristics, sources of clinical trial information and motives to participate in clinical trials among the general population in the USA. RESULTS Of 3,772 US adults, 41.3% reported not knowing about clinical trials. Prevalence of having no knowledge of clinical trials was higher among Hispanic adults (51.8%) and non-Hispanic Black adults (41.8%) compared with non-Hispanic White adults (37.4%; p=0.013). Other significant predictors of knowledge about clinical trials included higher education, online health information-seeking behaviour and patient portal access. Most respondents (73.2%) reported that healthcare providers were the most trusted source of information. Helping other people (71.6%) was the primary motivation for clinical trial participation, followed by financial compensation (12.5%) and receiving better treatment (5.1%). CONCLUSION There is a gap in knowledge about clinical trials among the US population. Development of multimodal approaches, including online and offline information broadcasting, is needed to improve knowledge and clinical trial recruitment in diverse populations.
Collapse
Affiliation(s)
- Sandhya Yadav
- University of Florida College of Public Health and Health Professions, Gainesville, USA
| | - Alissa Todd
- University of Florida College of Public Health and Health Professions, Gainesville, USA
| | | | - Amir A Tabriz
- Moffitt Cancer Center Tampa, USA and University of South Florida Morsani College of Medicine, Tampa, USA
| | | | - Kea Turner
- Moffitt Cancer Center Tampa, USA and University of South Florida Morsani College of Medicine, Tampa, USA
| | - Young-Rock Hong
- University of Florida College of Public Health and Health Professions, Gainesville, USA.
| |
Collapse
|
3
|
Aabdien M, Abdallah I, Bougmiza MI, Siepmann T, Illigens B. Perceptions and attitudes toward participation in clinical research in the Eastern Mediterranean Region: A systematic review. Medicine (Baltimore) 2022; 101:e29959. [PMID: 35984206 PMCID: PMC9388020 DOI: 10.1097/md.0000000000029959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
INTRODUCTION Successful recruitment of participants into clinical research has always been challenging and is affected by many factors. This systematic review aimed to explore the perceptions and attitudes as well as identify the factors affecting the participation in clinical research among the Eastern Mediterranean Regional Office countries' population. METHODS A systematic search of the literature was conducted to explore attitudes or perceptions of the general public or patients towards participation in clinical research. PubMed, Pro-Quest Central, World Health Organizations Index Medicus for the Eastern Mediterranean Region, and Google Scholar were searched. Studies were considered eligible for inclusion if they presented primary data and were conducted in one of the Eastern Mediterranean Regional Office countries. A data extraction sheet was used to record the following: year, country, aim, population, sample size, study design, data collection, and setting. The identified factors from the included studies were categorized into motivators and barriers. RESULTS In total, 23 original research articles were identified that addressed perceptions or attitudes towards clinical research participation. Six main motivators and barriers of research participation among patients, the general public, and patient family members were identified. The most common cited motivators included personal benefits to the individual, altruism and the desire to help others, the research process, the influence of the physician, family encouragement, and religion. Concerns regarding safety, confidentiality, and other factors in addition to the research process, lack of trust in healthcare providers or healthcare system, lack of interest in research and no perceived personal benefit, religious concerns, and family/cultural concerns were the most cited barriers to participation. CONCLUSION The identified motivators and barriers are essential to tackle during clinical research planning among the population of Eastern Mediterranean Regional Office countries. Further research is needed to assess the attitudes and perceptions of individuals approached to participate in trials.
Collapse
Affiliation(s)
- Mohamed Aabdien
- Community Medicine Training Program: Medical Education, Hamad Medical Corporation, Doha, Qatar
- Division of Health Care Sciences, Center for Clinical Research and Management Education Dresden International University, Dresden, Germany
- * Correspondence: Mohamed Aabdien, Community Medicine Training Program, Medical Education, Hamad Medical Corporation, Doha, Qatar (e-mail: )
| | | | - Mohamed Iheb Bougmiza
- Workforce Development & Training – Family & Community Medicine Department, Primary Health Care Corporation, Doha, Qatar
| | - Timo Siepmann
- Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Ben Illigens
- Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| |
Collapse
|
4
|
Huang R, Rao H, Lv F, Nan Y, Ren W, Huang Y, Li J, Tang H, Huang Y, Chalasani N, Wei L. Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey. Ther Innov Regul Sci 2022; 56:464-473. [PMID: 35171499 DOI: 10.1007/s43441-022-00380-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 01/20/2022] [Indexed: 02/05/2023]
Abstract
BACKGROUND Many new therapies of non-alcoholic fatty liver disease are being evaluated in clinical trials (CTs), but few of these trials involved sites in China. We evaluated influencing factors of Chinese patients' perspectives in participation in CTs of non-alcoholic fatty liver disease. METHODS A questionnaire was designed to be completed by patients with non-alcoholic fatty liver disease at eight affiliated hospitals across China. RESULTS 428 patients were included in this analysis, 63% were male and median age was 37.9 years (30.0-44.0). 54% patients rated "to help others" and 30% "to improve my health status" as the greatest benefit from CTs. The most important concerns were safety (43%) and patients' benefit (26%). Improving liver fibrosis or cirrhosis (53%) and reducing fat in liver (21%) were desired efficacy of new drugs. Possibility of being treated with a placebo for up to 2-6 years played an influential (21%) or very influential (73%) role on participation. Lower education level, lower body mass index, and cirrhosis were positively associated with acceptance of liver biopsies. Anxiety of adverse effects of the new drug and requirement of 2-3 liver biopsies were negatively associated with patients' attitudes toward participating in the trial. CONCLUSION More than one-third of Chinese patients with NAFLD in this survey are willing to participate in CTs of NASH. For CTs of NASH treatment, potential effects on reversing fibrosis or cirrhosis would positively influence, while adverse effects of the new drug and requirement of multiple liver biopsies would negatively influence participation in our study.
Collapse
Affiliation(s)
- Rui Huang
- Peking University People's Hospital, Peking University Hepatology Institute, No. 11 Xizhimen South Street, Beijing, 100044, China
| | - Huiying Rao
- Peking University People's Hospital, Peking University Hepatology Institute, No. 11 Xizhimen South Street, Beijing, 100044, China
| | - Fangfang Lv
- Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, No. 3 Qichun East Street, Hangzhou, Zhejiang, China
| | - Yuemin Nan
- The Third Hospital of Hebei Medical University, No. 139 Ziqiang Street, Shijiazhuang, Hebei, China
| | - Wanhua Ren
- Shandong Provincial Hospital Affiliated To Shandong University, No. 324, Jingwu Street, Jinan, Shandong, China
| | - Yan Huang
- Xiangya Hospital Central South University, No. 87 Xiangya Street, Changsha, Hunan, China
| | - Jun Li
- Jiangsu Province Hospital, No. 300 Guangzhou Street, Nanjing, Jiangsu, China
| | - Hong Tang
- West China School of Medicine/West China Hospital, Sichuan University, No. 37 Guoxue Street, Chengdu, Sichuan, China
| | - Yuan Huang
- Beijing Tsinghua Changgung Hospital, No. 168 Litang Street, Beijing, China
| | - Naga Chalasani
- Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 1050 Wishard Boulevard, RG 4100, Indianapolis, IN, 46202, USA
| | - Lai Wei
- Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, No. 168, Litang Road, Changping District, Beijing, 102218, China.
| |
Collapse
|
5
|
Alghamdi MA, Alghamdi SM, Bahadur YA, Asiri MA, AlHussain HA, Alhebshi AS, Alothman MO, Al-Omair AS, Alghamdi AA, Qanat AS, Aqeeli MO, Alsuhaibani AA, Alshehri SM, Alotain IM, Mail NK, Alhashemi HH, Alassaf HA. Scholarly Activity of Radiation Oncologists in High-Income Developing Countries: Saudi Arabia as an Example. JCO Glob Oncol 2021; 7:378-383. [PMID: 33720748 PMCID: PMC8081503 DOI: 10.1200/go.20.00449] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
PURPOSE To examine the trends and quality metrics of publications by radiation oncologists in Saudi Arabia. METHODS PubMed was searched using names of all Saudi radiation oncologists to retrieve published articles between January 2010 and December 2019. International collaboration, journal impact factor and country of origin, and number of citations were collected. Each article was assessed for epidemiologic type and independently assigned a level of evidence (LOE) by two authors. The trend in publications was examined and compared in the first and second 5-year periods (2010-2014 and 2015-2019) using relevant parameters. RESULTS A total of 186 publications were found and included. The most common type of research was cohort studies followed by case reports and case series in 24%, 14%, and 13% of all publications, respectively. Dosimetry, clinical, and preclinical studies formed 7%, 8.6%, and 7.5% of the total publications, respectively. The LOE was I, II, III, IV, and not applicable in 8.6%, 22%, 25.8%, 29%, and 14.5% of the included publications, respectively. Comparing the first and second 5-year periods, there was an increase in international collaboration (P < .001) in the second period. The number of citations (P < .001) and journal impact factor (P = .028) were lower in the second period. LOE and publications in international journals were not statistically different between the two periods. CONCLUSION Although radiation oncology research activity in Saudi Arabia has gained momentum in terms of volume and international collaboration over time, the LOE has not improved. This calls for a national effort to make the contribution to the literature a priority, allocate adequate resources, and apply appropriate measures to enhance research productivity and quality.
Collapse
Affiliation(s)
- Majed A Alghamdi
- Department of Medicine, College of Medicine, Al Baha University, Al Baha, Saudi Arabia.,Radiation Oncology, Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard, Jeddah, Saudi Arabia
| | - Suliman M Alghamdi
- Radiation Oncology, Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard, Jeddah, Saudi Arabia.,King Abdullah International Medical Research Center, Jeddah, Saudi Arabia
| | - Yasir A Bahadur
- Department of Radiology, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
| | - Mushabbab A Asiri
- Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Hussain A AlHussain
- Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Adnan S Alhebshi
- Radiation Oncology, Oncology Institute, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia
| | - Majid O Alothman
- Radiation Oncology, Oncology Institute, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia
| | - Ameen S Al-Omair
- Radiation Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | | | - Ahmed S Qanat
- College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Mohammed O Aqeeli
- College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Abdullah A Alsuhaibani
- Radiation Oncology, University Oncology Center, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia
| | - Salem M Alshehri
- Radaition Oncology, Department of Oncology, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.,King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Ibrahim M Alotain
- Radaition Oncology, Department of Oncology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
| | - Noor K Mail
- Radiation Oncology, Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard, Jeddah, Saudi Arabia.,King Abdullah International Medical Research Center, Jeddah, Saudi Arabia
| | - Hashem H Alhashemi
- Department of Internal Medicine, King Abdulaziz Medical City, Ministry of National Guard, Jeddah, Saudi Arabia.,King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Hossam A Alassaf
- Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| |
Collapse
|
6
|
Tabba' A, Kateb L, Al-Hussaini M. Clinical Trials in Social Media: Content Analysis of YouTube Videos in Arabic Language (Preprint). Interact J Med Res 2020. [DOI: 10.2196/19005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Al-Rawashdeh N, Damsees R, Al-Jeraisy M, Al Qasim E, Deeb AM. Knowledge of and attitudes toward clinical trials in Saudi Arabia: a cross-sectional study. BMJ Open 2019; 9:e031305. [PMID: 31641002 PMCID: PMC6830621 DOI: 10.1136/bmjopen-2019-031305] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVES Clinical trials (CTs) are considered an important method for developing new treatments and providing access to potentially effective drugs that are still under investigation. Measuring the public's knowledge of and attitudes toward CTs is important for assessing their readiness for and acceptance of human drug testing, which has previously not been assessed in the Kingdom of Saudi Arabia (KSA). The objective of this study is to explore the Saudi public's knowledge of and attitudes toward CTs as well as participation in trials to test new or approved drugs. DESIGN Cross-sectional. SETTING The 2016 Al Jenadriyah cultural/heritage festival in Riyadh, KSA. PARTICIPANTS Participating booths and exhibition halls, as well as festival visitors, were approached to participate in the study. PRIMARY AND SECONDARY OUTCOME MEASURES Knowledge of and attitudes toward CTs. RESULTS The final number of participants was 938. The responses were converted to a percentage mean score (out of 100) for each knowledge-related response and attitude. The total mean knowledge score was 56.8±24.8 and the attitude-related score was 61.5±28.0. Although most of the participants supported testing approved or off-label and new drugs on adult and paediatric patients, only a third (30.5%) agreed that new drugs could be tested on healthy volunteers. The results indicated that gender, educational level, income, medical background, age and health insurance were independently associated with the level of knowledge of CTs. In terms of attitudes toward CTs, the factors that were independently associated were gender, educational level and medical background. CONCLUSIONS The Saudi public has a low level of knowledge and a moderately positive attitude toward CTs. There is a moderate positive correlation between the two factors such that as knowledge of CTs increases, the Saudi public will hold more positive attitudes toward CTs.
Collapse
Affiliation(s)
- Nedal Al-Rawashdeh
- Research Office, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- The Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia
| | - Rana Damsees
- Research Office, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- The Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia
| | - Majed Al-Jeraisy
- Research Office, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia
| | - Eman Al Qasim
- Research Office, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia
| | - Ahmad M Deeb
- Research Office, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia
| |
Collapse
|
8
|
Jiang S, Liu P, Yang S, Yang J, Wu D, Fang H, Qin Y, Zhou S, Xu J, Sun Y, Mo H, Gui L, Xing P, Lan B, Zhang B, Tang L, Sun Y, Shi Y. Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. BMJ Open 2019; 9:e028589. [PMID: 31154312 PMCID: PMC6549607 DOI: 10.1136/bmjopen-2018-028589] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2018] [Revised: 04/05/2019] [Accepted: 04/29/2019] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES Patients' stress and satisfaction concerning cancer clinical trials (CCT) may affect study accrual and quality. Our study aimed to evaluate stress and satisfaction in CCT and the influencing factors. DESIGN Cross-sectional analysis done by a questionnaire after informed consent. SETTING Cancer Hospital, Chinese Academy of Medical Sciences. PARTICIPANTS 199 CCT participants. Primary and secondary outcome measures self-assessed stress and satisfaction in CCT. RESULTS Among 199 participants, 83.9% would join CCT again; 72.9% had enough time to decide on trial participation; 73.9% claimed complete awareness of CCT; 3.5% doubted CCT's significance and scientific quality; 33.2% deemed CCT time-consuming; 73.9% scored satisfaction ≥9/10; and 25.6% claimed moderate to severe stress. Positive factors for satisfaction were enough decision time (OR=0.36, p=0.0003), better impressions of doctors (OR=0.41, p=0.047) and less time-consuming trials (OR=0.43, p<0.0001). Individuals with more prior uninsured medical expenses (OR=1.23, p=0.026), less time consumption (OR=2.35, p<0.0001) and more tests in CCT (OR=0.64, p=0.035) were less likely to experience stress. Phase III study participants bore less stress than phase II (OR=0.29, p=0.032) but more than phase I (OR=1.18, p=0.009). CONCLUSIONS Our study addressed factors influencing CCT participants' stress and satisfaction. We suggested measures to improve patients' experiences in CCT. TRIAL REGISTRATION NUMBER NCT03412344; Pre-results.
Collapse
Affiliation(s)
- Shiyu Jiang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Peng Liu
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Sheng Yang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Jianliang Yang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Dawei Wu
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- National GCP Center for Anticancer Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Hong Fang
- National GCP Center for Anticancer Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yan Qin
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Shengyu Zhou
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Jianping Xu
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yongkun Sun
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Hongnan Mo
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Lin Gui
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Puyuan Xing
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Bo Lan
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Bo Zhang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Le Tang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yan Sun
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- National GCP Center for Anticancer Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yuankai Shi
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- National GCP Center for Anticancer Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
9
|
Salem R, Matar C, Assi R, Alameddine R, Temraz S, Shamseddine A, Mukherji D. Perceptions and Attitudes of Cancer Patients and Caregivers Towards Enrollment in Clinical Trials in Lebanon. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2019; 34:334-338. [PMID: 29196906 DOI: 10.1007/s13187-017-1307-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The rates of participation in oncology clinical trials (CTs) are relatively lower in the Middle East compared to other areas in the world. Many social and cultural factors underlie the patients' reluctance to participate. To probe the knowledge, attitudes, and perceptions of patients with cancer and their caregivers regarding participation in CTs at our tertiary referral center in Lebanon, we interviewed 210 patients and caregivers visiting the outpatient clinics in the Naef Basile Cancer Institute at the American University of Beirut. A questionnaire was derived from literature and administered in Arabic. The study was approved by the Institutional Review Board (IRB). Two hundred individuals agreed to answer the questionnaire. The majority of participants (90.5%) were Lebanese with the remaining being non-Lebanese Arabs. Eighty-nine participants (45%) were aware of the concepts of CTs. Eighty-two respondents (41%) would participate in phase I CTs. Twenty-nine individuals (14.5%) agree to be enrolled in CTs with the approval of their family members only. One hundred twenty-nine subjects (64.5%) stated that they would refuse enrollment in a CT where they might receive placebo. Eighty-eight (44%) of participants considered that medical records could be reviewed for research without consent while 54% agreed that samples collected during clinical workup could be used for research without the consent of the patient. There are several social and demographic correlates for participation in CTs. Raising awareness and overcoming barriers of misconception are keys to promote participation in CTs in Lebanon.
Collapse
Affiliation(s)
- Rana Salem
- Hematology and Oncology Division, Department of Internal Medicine, American University of Beirut, P.O. Box 113-6044, Beirut, Lebanon
| | - Charbel Matar
- Department of Internal Medicine, American University of Beirut, P.O. Box 113-6044, Beirut, Lebanon
| | - Rita Assi
- Hematology and Oncology Division, Department of Internal Medicine, American University of Beirut, P.O. Box 113-6044, Beirut, Lebanon
| | - Raafat Alameddine
- Hematology and Oncology Division, Department of Internal Medicine, American University of Beirut, P.O. Box 113-6044, Beirut, Lebanon
| | - Sally Temraz
- Hematology and Oncology Division, Department of Internal Medicine, American University of Beirut, P.O. Box 113-6044, Beirut, Lebanon
| | - Ali Shamseddine
- Hematology and Oncology Division, Department of Internal Medicine, American University of Beirut, P.O. Box 113-6044, Beirut, Lebanon
| | - Deborah Mukherji
- Hematology and Oncology Division, Department of Internal Medicine, American University of Beirut, P.O. Box 113-6044, Beirut, Lebanon.
| |
Collapse
|
10
|
Tohid H, Choudhury SM, Agouba S, Aden A, Ahmed LHM, Omar O, Chagoury O, Taheri S. Perceptions and attitudes to clinical research participation in Qatar. Contemp Clin Trials Commun 2017; 8:241-247. [PMID: 29696215 PMCID: PMC5898555 DOI: 10.1016/j.conctc.2017.10.010] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 10/06/2017] [Accepted: 10/30/2017] [Indexed: 12/23/2022] Open
Abstract
Recruitment into clinical research studies is a major challenge. This study was carried out to explore the perceptions and attitudes towards clinical research participation among the general public in Qatar. A population based questionnaire study was carried out at public events held in Qatar. Residents of Qatar, 18 years or above in age were surveyed, anonymously, following verbal consent. Descriptive and multivariate analyses were conducted. We administered 2517 questionnaires to examine clinical research participation, of which 2379 complete forms were analyzed. Those who had previously been approached to participate in research completed a more detailed assessment. Data showed that only 5.7% participants (n = 134) had previously been approached to participate in a clinical research study. Of these 63.4% (n = 85) had agreed to participate while 36.6% (n = 49) had declined. The main reasons for declining participation included: time constraint (47.8%, n = 11), 'fear' (13.0%, n = 3), lack of awareness about clinical research (8.7%, n = 2) and lack of interest (8.7%, n = 2). 'To help others' (31.8%, n = 27) and 'thought it might improve my access to health care' (24.7%, n = 21) were the prime motivators for participation. There was a general agreement among participants that their previous research experience was associated with positive outcomes for self and others, that the research conduct was ethical, and that opportunities for participation will be welcomed in future. More than ten years of stay within Qatar was a statistically significant determinant of willingness to participate, adjusted odds ratio 5.82 (95% CI 1.93-17.55), p = 0.002. Clinical research participation in Qatar needs improvement. Time constraints, lack of trust in and poor awareness about clinical research are main barriers to participation. Altruism, and improved health access are reported as prime motivators. Deeper insight in to the factors affecting clinical research participation is needed to devise evidence based policies for improvement in recruitment strategies.
Collapse
Affiliation(s)
- Hiba Tohid
- Department of Medicine and Clinical Research Core, Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar
| | - Sopna M Choudhury
- Department of Medicine and Clinical Research Core, Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar
| | - Sahar Agouba
- Department of Medicine and Clinical Research Core, Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar
| | - Abdi Aden
- Department of Medicine and Clinical Research Core, Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar
| | - Lina H M Ahmed
- Department of Medicine and Clinical Research Core, Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar
| | - Omar Omar
- Department of Medicine and Clinical Research Core, Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar
| | - Odette Chagoury
- Department of Medicine and Clinical Research Core, Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar
| | - Shahrad Taheri
- Department of Medicine and Clinical Research Core, Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, Doha, Qatar.,Department of Medicine, Weill Cornell Medicine in New York, New York, USA
| |
Collapse
|
11
|
Šolić I, Stipčić A, Pavličević I, Marušić A. Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials. Biochem Med (Zagreb) 2017; 27:259-269. [PMID: 28694716 PMCID: PMC5493165 DOI: 10.11613/bm.2017.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 05/11/2017] [Indexed: 11/23/2022] Open
Abstract
Introduction Despite increased visibility of clinical trials through international trial registries, patients often remain uninformed of their existence, especially if they do not have access to adequate information about clinical research, including the language of the information. The aim of this study was to describe the context for transparency of clinical trials in Croatia in relation to countries in Central and Eastern Europe, and to assess how informed Croatian patients are about clinical trials and their accessibility. Materials and methods We assessed the transparency of clinical trials from the data available in the public domain. We also conducted an anonymous survey on a convenience sample of 257 patients visiting two family medicine offices or an oncology department in south Croatia, and members of national patients’ associations. Results Despite legal provisions for transparency of clinical trials in Croatia, they are still not sufficiently visible in the public domain. Among countries from Central and Eastern Europe, Croatia has the fewest number of registered trials in the EU Clinical Trials Registry. 66% of the patients in the survey were aware of the existence of clinical trials but only 15% were informed about possibilities of participating in a trial. Although 58% of the respondents were willing to try new treatments, only 6% actually participated in a clinical trial. Only 2% of the respondents were aware of publicly available trial registries. Conclusions Our study demonstrates that there is low transparency of clinical trials in Croatia, and that Croatian patients are not fully aware of clinical trials and the possibilities of participating in them, despite reported availability of Internet resources and good communication with their physicians. There is a need for active policy measures to increase the awareness of and access to clinical trials to patients in Croatia, particularly in their own language.
Collapse
Affiliation(s)
- Ivana Šolić
- Medical student, University of Split School of Medicine, Split, Croatia
| | - Ana Stipčić
- Department of Health Studies, University of Split, Split, Croatia
| | - Ivančica Pavličević
- Department of Family Medicine, University of Split School of Medicine, Split, Croatia
| | - Ana Marušić
- Department of Research in Biomedicine and Health, University of Split School of Medicine, Split, Croatia.,Cochrane Croatia
| |
Collapse
|
12
|
Lim Y, Lim JM, Jeong WJ, Lee KH, Keam B, Kim TY, Kim TM, Han SW, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Im SA. Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. Cancer Res Treat 2017; 49:1033-1043. [PMID: 28392549 PMCID: PMC5654169 DOI: 10.4143/crt.2016.413] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 01/03/2017] [Indexed: 12/15/2022] Open
Abstract
PURPOSE The purpose of this study was to assess current levels of awareness of clinical trials (CTs), perceptions regarding their benefits and willingness to participate to CTs among Korean cancer patients. MATERIALS AND METHODS From December 2012 to August 2015, we distributed questionnaires to cancer patients receiving systemic anti-cancer therapy at Seoul National University Hospital, Seoul, Korea. RESULTS A total of 397 out of 520 requested patients (76.3%) responded to the survey. Among the 397 patients, 62.5% were female and the median age was 52 years. Overall, 97.4% (387/397) answered that they have at least heard of CTs. When asked about their level of awareness, 23.8% (92/387) answered that they could more than roughly explain about CTs. The average visual analogue scale score of CT benefit in all patients was 6.43 (standard deviation, 2.20). Patients who were only familiar with the term without detailed knowledge of the contents had the least expectation of benefit from CTs (p=0.015). When asked about their willingness to participate in CTs, 56.7% (225/397) answered positively. Patients with higher levels of awareness of CTs showed higher willingness to participate (p < 0.001). Heavily treated patients and patients with previous experience regarding CTs also showed a higher willingness to participate (p < 0.001). The perceived benefit of CTs was higher in the group willing to participate (p=0.026). CONCLUSION The patient's level of awareness regarding CTs was positively related to the positive perception and willingness to participate. Although the general awareness of CTs was high, a relatively large proportion of patients did not have accurate knowledge; therefore, proper and accurate patient education is necessary.
Collapse
Affiliation(s)
- Yoojoo Lim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Translational Medicine Major, Department of Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Jee Min Lim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Won Jae Jeong
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Kyung-Hun Lee
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Bhumsuk Keam
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Tae-Yong Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Tae Min Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Sae-Won Han
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Do Youn Oh
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Translational Medicine Major, Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Dong-Wan Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Translational Medicine Major, Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Tae-You Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Translational Medicine Major, Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
| | - Dae Seog Heo
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Yung-Jue Bang
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea
| | - Seock-Ah Im
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.,Translational Medicine Major, Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.,Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| |
Collapse
|
13
|
Almutairi KM, Alonazi WB, Alodhayani AA, Vinluan JM, Moussa M, Al-Ajlan AS, Alsaleh K, Alruwaimi D, Alotaibi NE. Barriers to Cancer Clinical Trial Participation Among Saudi Nationals: A Cross-Sectional Study. JOURNAL OF RELIGION AND HEALTH 2017; 56:623-634. [PMID: 27631996 DOI: 10.1007/s10943-016-0306-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
This study aims to determine the factors that act as barriers to Saudi cancer patients in participating in a clinical trial (CT). A total of 244 patients from two different tertiary level hospitals (King Khalid University Hospital and King Fahad Medical City Hospital) in Riyadh, Saudi Arabia, participated in this cross-sectional study. The participants were interviewed by a trained researcher between September and November 2015. All respondents answered a three-part questionnaire which includes demographics, clinical information, and questions related to awareness of CTs, willingness to participate, and factors affecting participation in CTs. The mean age of the participants was 50.83, and 57 % of the participants were females. Most of the participants (63.5 %) were currently being treated for cancer, and 28 % were diagnosed with breast cancer followed by colorectal cancer. Health status or quality of life was self-reported as acceptable by 27.9 % of the participants, and 25 % of the participants at stage II of cancer. The factors that act as barriers to Saudi cancer patients in participating in a CT can be categorized into patient- and physician-related factors. Patient factors include lack of awareness, misconception and fear in participating in CTs; physician-related factors comprise of lack of encouragement from physician to patients in participating in a CT. The study identified few major barriers to participation in CTs. Increased patient awareness and recruitment strategies are required to increase accrual of patients including training for physicians and disseminating easy-to-read tools to the public.
Collapse
Affiliation(s)
- Khalid M Almutairi
- Department of Community Health Science, College of Applied Medical Science, King Saud University, Riyadh, Saudi Arabia.
| | - Wadi B Alonazi
- College of Business Administration, King Saud University, Riyadh, Saudi Arabia
| | - Abdulaziz A Alodhayani
- Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Jason M Vinluan
- Department of Community Health Science, College of Applied Medical Science, King Saud University, Riyadh, Saudi Arabia
| | - Mahaman Moussa
- Medical Surgical Department, College of Nursing, King Saud University, Riyadh, Saudi Arabia
| | - Abdulrahman S Al-Ajlan
- Clinical Laboratories Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia
| | - Khalid Alsaleh
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Duna Alruwaimi
- Clinical Laboratories Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia
| | - Nader E Alotaibi
- College of Business Administration, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
14
|
Bouida W, Grissa MH, Zorgati A, Beltaief K, Boubaker H, Sriha A, Boukef R, Nouira S. Willingness to participate in health research: Tunisian survey. BMC Med Ethics 2016; 17:47. [PMID: 27492385 PMCID: PMC4973371 DOI: 10.1186/s12910-016-0131-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Accepted: 07/28/2016] [Indexed: 11/25/2022] Open
Abstract
Background Few studies have identified the willingness rate of developing countries population to be enrolled in clinical trials. Methods All participants including patients (n = 612), healthy volunteers (n = 354) and doctors (n = 134) completed a questionnaire to examine factors affecting the consent to participate in medical research. Results Overall, 80 % of the included population agree to participate in health research. This rate was lower for trials dealing with life-threatening diseases (38 %). Altruism and perceived risk of harm were the main reason to respectively accept or refuse to participate in clinical trials. Factors significantly associated with willingness were: age <40 years (Odds Ratio (OR) 1.6 [95 % Confidence Interval (CI) 1.2-2.1]) and prior history of blood donation (OR 2.4 [95 % CI 1.7-3.5]). Conclusion Most participants expressed their willingness to be included in medical research especially if they are young or if they have history of blood donation. However, consent to participate is low when medical research required acute care. Electronic supplementary material The online version of this article (doi:10.1186/s12910-016-0131-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Wahid Bouida
- Emergency Department, Fattouma Bourguiba University Hospital Monastir, Monastir, 5000, Tunisia.,Research Laboratory (LR12SP18), University of Monastir, Monastir, Tunisia
| | - Mohamed Habib Grissa
- Emergency Department, Fattouma Bourguiba University Hospital Monastir, Monastir, 5000, Tunisia.,Research Laboratory (LR12SP18), University of Monastir, Monastir, Tunisia
| | - Asma Zorgati
- Emergency Department, Sahloul University Hospital, Sousse, Tunisia
| | - Kaouthar Beltaief
- Emergency Department, Fattouma Bourguiba University Hospital Monastir, Monastir, 5000, Tunisia.,Research Laboratory (LR12SP18), University of Monastir, Monastir, Tunisia
| | - Hamdi Boubaker
- Emergency Department, Fattouma Bourguiba University Hospital Monastir, Monastir, 5000, Tunisia.,Research Laboratory (LR12SP18), University of Monastir, Monastir, Tunisia
| | - Asma Sriha
- Community Medicine Department, Fattouma Bourguiba University Hospital Monastir, Monastir, Tunisia
| | - Riadh Boukef
- Emergency Department, Sahloul University Hospital, Sousse, Tunisia.,Research Laboratory (LR12SP18), University of Monastir, Monastir, Tunisia
| | - Semir Nouira
- Emergency Department, Fattouma Bourguiba University Hospital Monastir, Monastir, 5000, Tunisia. .,Research Laboratory (LR12SP18), University of Monastir, Monastir, Tunisia.
| |
Collapse
|